AI Article Synopsis
- A study assessed the effectiveness of pneumococcal conjugate vaccines (PCV-10 and PCV-13) against invasive Streptococcus pneumoniae in Canada from 2011 to 2017, analyzing 9,166 isolates.
- The study found a significant decrease in the prevalence of serotypes covered by both vaccines over time, with PCV-13 showing better coverage overall compared to PCV-10.
- Particularly, PCV-13 was more effective against multidrug-resistant strains, covering 53.3% of these isolates versus 14.6% for PCV-10, highlighting its superiority in combating resistant infections.
Article Abstract
To assess the coverage of invasive Streptococcus pneumoniae by pneumococcal conjugate vaccines (PCV)-10 and PCV-13 across Canada. In total, 9166 invasive S. pneumoniae isolates were collected as part of the SAVE 2011 to 2017 study. Serotyping was performed by the Quellung reaction and antimicrobial susceptibility testing was performed using CLSI methods. The proportion of both PCV-10 and PCV-13 serotypes decreased significantly (P < 0.0001) from 2011 (26.7% and 48.0%, respectively) to 2017 (11.2% and 26.2%). For central, western, and eastern regions of Canada, PCV-13 provided significantly greater (P < 0.0001) coverage at 33.7% (2060/6110), 23.0% (456/1985), and 36.3% (389/1071), respectively, compared to PCV-10 at 15.4% (939/6110), 10.1% (201/1985), and 15.8% (169/1071) coverage. PCV-13 provided significantly greater coverage (53.3%, 282/529) of multidrug-resistant (MDR) isolates (resistant to ≥3 antimicrobial classes) than PCV-10 (14.6%, 77/529, P < 0.0001). PCV-13 provided significantly greater coverage of invasive S. pneumoniae serotypes, as well as coverage of MDR isolates, than PCV-10.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.diagmicrobio.2020.115282 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Streptococcus pneumoniae, a major contributor to global morbidity and mortality, disproportionately affects children, the elderly, and immunocompromised individuals. Despite vaccination efforts, the challenge of serotype replacement highlights the ongoing struggle against invasive pneumococcal diseases (IPD) in Morocco, emphasizing the need for updated public health strategies and vaccine efficacy assessments.
Methods: This study was conducted at the Ibn Rochd University Hospital Center and the Mohammed VI University Hospital Center from 2019 to 2022, focusing on hospitalized children.
The potential impact of PCV-13, PCV-15 and PCV-20 vaccines in Colombia.
Vaccine
March 2024
Unisabana Center for Translational Science, Universidad de La Sabana, Chía, Colombia; Clínica Universidad de La Sabana, Chía, Colombia; School of Medicine, Universidad de La Sabana, Chía, Colombia; Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom. Electronic address:
Purpose: To provide information about which pneumococcal vaccine could have greater coverage in Colombia.
Methods: This is a retrospective analysis of patients diagnosed with invasive pneumococcal disease (IPD) between 2015 and 2019 in Bogotá, Colombia. We compared the theoretical serotype coverage of the available anti-pneumococcal vaccines (i.
Epidemiology of Serotypes in Jordan Amongst Children Younger than the Age of 5: A National Cross-Sectional Study.
Vaccines (Basel)
August 2023
Department of Pathology and Microbiology, King Abdullah University Hospital, Jordan University of Science and Technology, Irbid 22110, Jordan.
Article Synopsis
- Infections, particularly invasive pneumococcal diseases (IPDs), pose significant health risks in Jordan, and current data highlights the absence of pneumococcal conjugate vaccines (PCVs) in the national vaccination program.
- A study involving 1,015 pediatric patients identified the prevalence of common pneumococcal serotypes, with notable findings including a high PCR positivity rate and identified serotypes such as 6B and 14.
- This research underscores the urgent need to introduce PCVs in Jordan's vaccination schedule, as it provides critical data on prevalent serotypes to guide vaccine selection.
Serotype distribution and antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates among adult and elderly population before and after introduction of pneumococcal conjugate vaccine in Casablanca, Morocco.
BMC Infect Dis
January 2023
Department of Microbiology, Faculty of Medicine and Pharmacy of Casablanca, Hassan II University of Casablanca, Casablanca, Morocco.
Background: Streptococcus pneumoniae (S. pneumoniae), remains a major cause of mortality and morbidity worldwide. The objective of this study was to determine the trends of invasive pneumococcal diseases (IPD) in adult and elderly population in Casablanca (Morocco) before and after introduction of pneumococcal conjugate vaccine (PCV) by determining the distribution of pneumococcal serotypes and antibiotic resistance profile of isolated strains.
View Article and Find Full Text PDFMolecular Characterization of from Patients Diagnosed with Pneumonia: Recommendation for Vaccination Program.
Med J Islam Repub Iran
December 2022
Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.
Infections caused by () have remained a significant public health concern worldwide. In developed countries, the highest prevalence of has been reported among the elderly. The aim of this study was to evaluate the coverage of genotypes in the 13-valent pneumococcal conjugate vaccine (PCV-13) in the Iranian elderly population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!